Glaucoma Therapies: Medical, Laser, MIGS & Filtration Surgery
A comprehensive guide to glaucoma management encompassing pharmacotherapy, Selective Laser Trabeculoplasty (SLT), MIGS micro-stents, and trabeculectomy.
Article Table of Contents
1. Comprehensive Overview
The core tenet of glaucoma management is achieving an individualized 'Target IOP'—the pressure range at which further optic nerve damage is unlikely to occur within the patient's estimated lifespan.
Triad of Glaucoma Therapeutics:
1. Pharmacotherapy (Topical Drops): - Outflow Enhancers: Prostaglandin F2a analogues (Latanoprost, Travoprost, Bimatoprost) - first-line agents increasing uveoscleral outflow by up to 35%. - Inflow Suppressors: Beta-blockers (Timolol), Carbonic Anhydrase Inhibitors (Dorzolamide, Brinzolamide), and Alpha-2 Agonists (Brimonidine). - Preservative-Free Fixed-Combination Formulations to improve compliance and protect the ocular surface.
2. Ophthalmic Lasers: - Selective Laser Trabeculoplasty (SLT): 532nm Q-switched laser selectively targeting pigmented trabecular cells without thermal damage, providing 20–30% IOP reduction. - Nd:YAG Laser Peripheral Iridotomy (LPI) for angle-closure relief. - Subthreshold MicroPulse Transscleral Cyclophotocoagulation (MP-TSCPC) for gentle ciliary body ablation.
3. Surgical Modalities: - Minimally Invasive Glaucoma Surgery (MIGS): Micro-stents (iStent, Hydrus, Xen, PreserFlo) ab-interno, offering rapid recovery and excellent safety profiles. - Guarded Filtration Surgery (Trabeculectomy + Mitomycin C): The gold standard for aggressive IOP reduction. - Aqueous Shunt Glaucoma Implants (Ahmed Glaucoma Valve, Baerveldt) for refractory, post-surgical, or neovascular glaucoma.
2. Symptoms & Warning Signs
If you observe any of the following symptoms repeatedly, an eye exam is strongly recommended:
- Stabilization of serial IOP tonometry within calculated target parameters
- Demonstrated stability on automated Humphrey Visual Fields and OCT RNFL trend analyses
- Transient mild stinging or conjunctival hyperemia following drop instillation
- Prostaglandin-associated periocular changes (increased eyelash length/pigmentation, iris hyperpigmentation)
3. Causes & Risk Factors
- 1Insufficient IOP lowering on monotherapy requiring escalation to combination drops or surgery
- 2Poor drop adherence or severe ocular surface toxicity from benzalkonium chloride (BAK) preservatives
- 3Documented structural or functional disease progression on maximal tolerated medical therapy (MTMT)
4. Treatments & Medical Management
5. Prevention & Daily Eye Care Advice
- Never discontinuing IOP-lowering drops even when vision feels clear and comfortable
- Utilizing preservative-free formulations to preserve long-term conjunctival and corneal health
- Undergoing baseline and repeat HVF perimetry and OCT RNFL scanning every 6–12 months to monitor stability
6. When to Seek Emergency Eye Care
Visit an immediate eye emergency center if you experience any of the following critical indicators:
- ⚠Severe ocular surface toxicity, allergic blepharoconjunctivitis, or drop intolerance
- ⚠Perceived shrinkage or new blind spots in the visual field
- ⚠Persistent ocular ache, indicating inadequate diurnal IOP control
- ⚠Signs of blebitis or endophthalmitis (pain, discharge, sudden vision drop) post-trabeculectomy
7. Frequently Asked Questions
Q:What is the proper technique for instilling glaucoma eye drops?
Instill a single drop into the lower conjunctival fornix, close eyelids gently without squeezing, and apply digital pressure over the medial lacrimal punctum for 2 minutes to maximize ocular absorption and prevent systemic uptake.